According to Huadong Medicine, on September 20, Huadong Medicine (000963) wholly-owned subsidiary Huadong Medicine (Hangzhou) Co., Ltd. announced an exclusive strategic cooperation with Hui Sheng Biological Pharmaceutical Co., Ltd. (referred to as "Huisheng Biotechnology"), a non-wholly-owned subsidiary of Sihuan Pharm (00460.HK), on the commercial rights in mainland China for their already marketed innovative product Huiyoujing (Furamino acid and Eglerin tablet), which is an SGLT-2 inhibitor for the treatment of type 2 diabetes in China.
华东医药与惠升生物宣布就新药惠优静达成战略合作
Huadong Medicine and Huisheng Biotechnology announced a strategic cooperation on the new drug Huiyoujing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated